Efficacy and safety of different chemotherapy regimens in treating combined small cell lung cancer

Li Guang; Liu Hongxia; Liu Jun

doi:10.3760/cma.j.issn.1673-4777.2017.01.012

Abstract：Objective To analyze the efficacy and safety of different chemotherapy regimens in treating combined small cell lung cancer(CSCLC).Methods Totally 178 cases of CSCLC from August 2001 to September 2015 in Jiamusi Central Hospital were enrolled;53 patients had chemotherapy with paclitaxel + cisplatin/carboplatin + etoposide(triple-drugs group);125 patients had chemotherapy with cisplatin/carboplatin + etoposide (dual-drugs group).Short-term efficacy and safety were evaluated.Overall survival(OS) and progression free survival(PFS) were analyzed.Results The effective rate and disease control rate in triple-drugs group were significantly higher than those in dual-drugs group[75.5％ (40/53) vs 52.0％ (65/125),P =0.005;92.5％ (49/53) vs 78.4％ (98/125),P =0.014].Incidences of bone marrow suppression,nausea,vomiting,liver function damage in triple-drugs group were significantly lower and incidences of diarrhea,erythra were significantly higher than those in dual-drugs group(P ＜ 0.01).The completion rate of chemotherapy in triple-drugs group was significantly higher than that in dual-drugs group[22.6％ (12/53) vs 16.0％ (20/125),P =0.008];but the tumor progression rate and death rate in triple-drugs group were higher than those in dual-drugs group [49.1％ (26/53) vs 36.8％ (46/125),P =0.008;11.3％ (6/53) vs 8.8％ (11/125),P =0.006].In triple-drugs group,OS and PFS were significantly better than those in dual-drugs group (P =0.042,0.035).Conclusions Chemotherapy with triple-drugs has higher short-term effective rate and lower adverse reaction rate than dual-drugs in the treatment of CSCLC,but it is also associated with higher rates of tumor progression and death.PFS and OS data of triple-drugs chemotherapy are good.